Condition: Advanced Solid Tumor · Diffuse Large B Cell Lymphoma · Lymphoma, T-Cell · Sponsor: Novartis Pharmaceuticals
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| H. Lee Moffitt Cancer Center and Research Institute | Tampa, Florida, United States | Withdrawn |
| Emory University School of Medicine | Atlanta, Georgia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Loyola University Medical Center | Maywood, Illinois, United States | Withdrawn |
| University of Maryland Medical Ctr | Baltimore, Maryland, United States | Withdrawn |
| Massachusetts General Hospital (MGH) | Boston, Massachusetts, United States | Recruiting |
| Dana Farber Cancer Institute (HARVARD) | Boston, Massachusetts, United States | Completed |
| University of Michigan Rogel Cancer Center | Ann Arbor, Michigan, United States | Withdrawn |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Completed |
| Roswell Park Cancer Institute | Buffalo, New York, United States | Withdrawn |
| NYU Langone Medical Center | New York, New York, United States | Completed |
| Weill Medical College of Cornell University | New York, New York, United States | Withdrawn |
+ 69 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04104776